Role of dopamine D3 receptors in thermoregulation: A reappraisal

NeuroReport

Volumn 11, Issue 1, 2000, Pages 221-225

  Perachon, Sylvie ^a   Betancur, Catalina ^b   Pilon, Catherine ^a   Rostène, William ^b   Schwartz, Jean Charles ^a   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

BP 897; D2 receptor; D3 receptor; Hypothermia; Knock out mice; Partial agonist; S 14297

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; BP 897; BROMOCRIPTINE; CF 25397; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PRAMIPEXOLE; QUINELORANE; UNCLASSIFIED DRUG; 2 NAPHTHYLAMINE; 7 (N,N DIPROPYLAMINO) 5,6,7,8 TETRAHYDRONAPHTHO(2,3 B)DIHYDRO 2,3 FURAN; 7 HYDROXY 2 N,N DIPROPYLAMINOTETRALIN; 7-(N,N-DIPROPYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHO(2,3-B)DIHYDRO-2,3-FURAN; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; CYCLIC AMP; DRD3 PROTEIN, HUMAN; DRD3 PROTEIN, MOUSE; DRD3 PROTEIN, RAT; DRUG DERIVATIVE; FORSKOLIN; FURAN DERIVATIVE; MITOGENIC AGENT; PIPERAZINE DERIVATIVE; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; HYPOTHERMIA; MALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; THERMOREGULATION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; HAMSTER; HUMAN; METABOLISM; MITOSIS; PHYSIOLOGY; WISTAR RAT;

2-NAPHTHYLAMINE; ANIMALS; BODY TEMPERATURE REGULATION; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; FURANS; HUMANS; MICE; MITOGENS; MITOSIS; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 0034676903     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200001170-00044     Document Type: Article

References (22)

1. Schwartz JC, Diaz J, Bordet R et al. Brain Res Rev 26, 236-242 (1998).
2. Pilla M, Perachon S, Sautel F et al. Nature 400, 371-375 (1999).
3. Sautel F, Griffon N, Lévesque D et al. Neuroreport 6, 329-332 (1995).
4. Shafer RA and Levant B. Psychopharmacology (Berl) 135, 1-16 (1998).
5. Millan MJ, Péglion J-L, Vian J et al. J Pharmacol Exp Ther 275, 885-898 (1995).
6. Audinot V, Newman-Tancredi A, Gobert A et al. J Pharmacol Exp Ther 287, 187-97 (1998).
7. Lévesque D, Diaz J, Pilon C et al. Proc Natl Acad Sci USA 89, 8155-8159 (1992).
8. Newman-Tancredi A, Cussac D, Audinot V et al. Mol Pharmacol 55, 564-574 (1999).
9. Griffon N, Pilon C, Sautel F et al. J Neurochem 68, 1-9 (1997).
10. Accili D, Fishburn CS, Drago J et al. Proc Natl Acad Sci USA 93, 1945-1949 (1996).
11. Sautel F, Griffon N, Sokoloff P et al J Pharmacol Exp Ther 275, 1239-1246 (1995).
12. Rivet JM, Audinot V, Gobert A et al. Eur J Pharmacol 265, 175-177 (1994).
13. Gobert A, Rivet JM, Audinot V et al. J Pharmacol Exp Ther 275, 899-913 (1995).
14. Lejeune F and Millan MJ. Eur J Pharmacol 275, R7-9 (1995).
15. Boulay D, Depoortere R, Perrault G et al. Neuropharmacology 38, 1389-1396 (1999).
16. Millan MJ, Gressier H and Brocco M. Eur J Pharmacol 321, R7-R9 (1997).
17. Costall B and Naylor R. Psychopharmacologia 43, 69-74 (1975).
18. Labrie F, Lagace L, Ferland L et al. Ann Clin Res 10, 109-119 (1978).
19. Sokoloff P, Giros B, Martres M-P et al Nature 347, 146-151 (1990).
20. Waters N, Svensson K, Haadsma-Svensson SR et al. J Neural Transm 94, 11-19 (1993).
21. Xu M, Koeltzow TE, Cooper DC et al. Synapse 31, 210-215 (1999).
22. Boulay D, Depoortere R, Rostene W et al. Neuropharmacology 38, 555-565 (1999).